{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:01:16Z","timestamp":1791860476531,"version":"4.3.4"},"reference-count":54,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["Ricerca Corrente LINEA 2\/40_25-RITMES"],"award-info":[{"award-number":["Ricerca Corrente LINEA 2\/40_25-RITMES"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chondrosarcomas (ChSs) are mesenchymal chemo- and radiation-resistant tumors, representing the second most frequently diagnosed bone sarcoma after osteosarcoma and 20% of all bone sarcomas. Most of ChS patients have a good prognosis after complete surgical resection. Conversely, patients with inoperable disease, due to the tumor location or metastatic dissemination, represent a great clinical challenge due to the lack of effective therapeutic options. In this study, to the best of our knowledge, we document, for the first time in human ChS tissues, the existence of CD-31- and Podoplanin-negative vascular-like channels containing red blood cells, allowing us to hypothesize the occurrence of vasculogenic mimicry (VM) in ChSs. By using patient-derived ChS cells and a stabilized ChS cell line, we demonstrate that ChS cells are able to form in vitro tubules apparently similar to those formed by endothelial cells. Further characterization of these vessels revealed the pivotal role of the Urokinase Plasminogen Activator Receptor (uPAR) in mediating the capability of ChS cells to form VM. Finally, we provide evidence that, unlike bevacizumab, which did not exert any effect, the uPAR-derived antiangiogenic peptide RI-3 behaves as a potent inhibitor of VM.<\/jats:p>","DOI":"10.3390\/cells15050392","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:19:23Z","timestamp":1771935563000},"page":"392","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Vincenzo","family":"Ingangi","sequence":"first","affiliation":[{"name":"Preclinical Models of Tumor Progression Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5406-2805","authenticated-orcid":false,"given":"Roberta","family":"Gatti","sequence":"additional","affiliation":[{"name":"Preclinical Models of Tumor Progression Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioconda","family":"Di Carluccio","sequence":"additional","affiliation":[{"name":"Preclinical Models of Tumor Progression Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5573-0935","authenticated-orcid":false,"given":"Vincenzo","family":"Di Vaia","sequence":"additional","affiliation":[{"name":"Preclinical Models of Tumor Progression Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-6082","authenticated-orcid":false,"given":"Margherita","family":"Cerrone","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Pathology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1999-2107","authenticated-orcid":false,"given":"Sara","family":"Scala","sequence":"additional","affiliation":[{"name":"Preclinical Models of Tumor Progression Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Maddalena","sequence":"additional","affiliation":[{"name":"Preclinical Models of Tumor Progression Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4510-0518","authenticated-orcid":false,"given":"Michele","family":"Gallo","sequence":"additional","affiliation":[{"name":"Musculoskeletal Surgery Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Fazioli","sequence":"additional","affiliation":[{"name":"Musculoskeletal Surgery Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2042-8672","authenticated-orcid":false,"given":"Chiara","family":"Ciardiello","sequence":"additional","affiliation":[{"name":"Preclinical Models of Tumor Progression Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-481X","authenticated-orcid":false,"given":"Michele","family":"Minopoli","sequence":"additional","affiliation":[{"name":"Preclinical Models of Tumor Progression Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vincenza","family":"Carriero","sequence":"additional","affiliation":[{"name":"Preclinical Models of Tumor Progression Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Gilbert, A., Tudor, M., Montanari, J., Commenchail, K., Savu, D.I., Lesueur, P., and Chevalier, F. (2023). Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions. Cancers, 15.","DOI":"10.3390\/cancers15071962"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00264-006-0212-x","article-title":"Pathology of Primary Malignant Bone and Cartilage Tumours","volume":"30","author":"Rozeman","year":"2006","journal-title":"Int. Orthop."},{"key":"ref_3","unstructured":"Hogendoorn, P., Fletcher, C., Bridge, J., and Mertens, F. (2013). WHO Classification of Tumours of Soft Tissue and Bone, IARC. World Health Organization."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gazendam, A., Popovic, S., Parasu, N., and Ghert, M. (2023). Chondrosarcoma: A Clinical Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072506"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ingangi, V., De Chiara, A., Ferrara, G., Gallo, M., Catapano, A., Fazioli, F., Di Carluccio, G., Peranzoni, E., Marigo, I., and Carriero, M.V. (2024). Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma. Cells, 13.","DOI":"10.3390\/cells13110977"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0046-8177(00)80248-8","article-title":"Microvasculature and VEGF Expression in Cartilaginous Tumors","volume":"31","author":"Ayala","year":"2000","journal-title":"Hum. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00003086-200204000-00011","article-title":"Pathologic Neovascularization in Cartilage Tumors","volume":"397","author":"McGough","year":"2002","journal-title":"Clin. Orthop."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Minopoli, M., Sarno, S., Di Carluccio, G., Azzaro, R., Costantini, S., Fazioli, F., Gallo, M., Apice, G., Cannella, L., and Rea, D. (2020). Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma. Cells, 9.","DOI":"10.3390\/cells9041062"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0002-9440(10)65285-6","article-title":"Angiosarcomas Express Mixed Endothelial Phenotypes of Blood and Lymphatic Capillaries: Podoplanin as a Specific Marker for Lymphatic Endothelium","volume":"154","author":"Soleiman","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/bs.acr.2020.06.001","article-title":"Vascular Mimicry: Triggers, Molecular Interactions and in Vivo Models","volume":"148","author":"Wechman","year":"2020","journal-title":"Adv. Cancer Res."},{"key":"ref_11","first-page":"270","article-title":"Podoplanin\u2014A specific marker for lymphatic endothelium expressed in angiosarcoma","volume":"83","author":"Soleiman","year":"1999","journal-title":"Verh. Dtsch. Ges. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","article-title":"Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry","volume":"155","author":"Maniotis","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Valdivia, A., Mingo, G., Aldana, V., Pinto, M.P., Ramirez, M., Retamal, C., Gonzalez, A., Nualart, F., Corvalan, A.H., and Owen, G.I. (2019). Fact or Fiction, It Is Time for a Verdict on Vasculogenic Mimicry?. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00680"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1002\/jcb.28514","article-title":"Expression Profiling of Long Noncoding RNAs Associated with Vasculogenic Mimicry in Osteosarcoma","volume":"120","author":"Ren","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cncr.24844","article-title":"Angiogenesis and Vascular Targeting in Ewing Sarcoma: A Review of Preclinical and Clinical Data","volume":"116","author":"DuBois","year":"2010","journal-title":"Cancer"},{"key":"ref_16","first-page":"1609","article-title":"Vasculogenic Mimicry Is Associated with Poor Survival in Patients with Mesothelial Sarcomas and Alveolar Rhabdomyosarcomas","volume":"25","author":"Sun","year":"2004","journal-title":"Int. J. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-0716-2403-6_11","article-title":"Histochemical Staining of Vasculogenic Mimicry","volume":"2514","author":"Imani","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Giordano, G., Merlini, A., Ferrero, G., Mesiano, G., Fiorino, E., Brusco, S., Centomo, M.L., Leuci, V., D\u2019Ambrosio, L., and Aglietta, M. (2021). EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing\u2019s Sarcoma and Chondrosarcoma. Cells, 10.","DOI":"10.3390\/cells10112893"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PAP.0000000000000293","article-title":"The 2020 WHO Classification of Tumors of Bone: An Updated Review","volume":"28","author":"Choi","year":"2021","journal-title":"Adv. Anat. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"842842","DOI":"10.1155\/2011\/842842","article-title":"Involvement of the Soluble Urokinase Receptor in Chondrosarcoma Cell Mobilization","volume":"2011","author":"Bifulco","year":"2011","journal-title":"Sarcoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1111\/j.1538-7836.2010.04075.x","article-title":"The Soluble Form of Urokinase Receptor Promotes Angiogenesis through Its Ser88-Arg-Ser-Arg-Tyr92 Chemotactic Sequence","volume":"8","author":"Bifulco","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/s41598-017-01425-9","article-title":"Retro-Inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas","volume":"7","author":"Carriero","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11568","DOI":"10.1038\/s41598-020-67289-8","article-title":"Angiogenesis Analyzer for ImageJ\u2014A Comparative Morphometric Analysis of \u201cEndothelial Tube Formation Assay\u201d and \u201cFibrin Bead Assay.\u201d","volume":"10","author":"Carpentier","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular Endothelial Growth Factor Signaling in Health and Disease: From Molecular Mechanisms to Therapeutic Perspectives","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10456-011-9251-z","article-title":"CD34 Marks Angiogenic Tip Cells in Human Vascular Endothelial Cell Cultures","volume":"15","author":"Siemerink","year":"2012","journal-title":"Angiogenesis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22356","DOI":"10.1038\/s41598-022-26456-9","article-title":"C-Type Lectin-like Receptor (CLEC)-2, the Ligand of Podoplanin, Induces Morphological Changes in Podocytes","volume":"12","author":"Tanaka","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1073\/pnas.131209798","article-title":"Expression and Functional Significance of VE-Cadherin in Aggressive Human Melanoma Cells: Role in Vasculogenic Mimicry","volume":"98","author":"Hendrix","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/s41467-017-02373-8","article-title":"Polarized Actin and VE-Cadherin Dynamics Regulate Junctional Remodelling and Cell Migration during Sprouting Angiogenesis","volume":"8","author":"Cao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12943-017-0631-x","article-title":"Vasculogenic Mimicry Signaling Revisited: Focus on Non-Vascular VE-Cadherin","volume":"16","author":"Oliver","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12964-024-01811-7","article-title":"Targeting the EphA2 Pathway: Could It Be the Way for Bone Sarcomas?","volume":"22","author":"Giordano","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3727\/096504021X16273798026651","article-title":"uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells","volume":"28","author":"Andreucci","year":"2022","journal-title":"Oncol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-020-00858-6","article-title":"Vasculogenic Mimicry in Carcinogenesis and Clinical Applications","volume":"13","author":"Luo","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1016\/j.ejca.2013.07.148","article-title":"Tumour Vasculogenic Mimicry Is Associated with Poor Prognosis of Human Cancer Patients: A Systemic Review and Meta-Analysis","volume":"49","author":"Cao","year":"2013","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10456-016-9500-2","article-title":"Tumor Vasculogenic Mimicry Predicts Poor Prognosis in Cancer Patients: A Meta-Analysis","volume":"19","author":"Yang","year":"2016","journal-title":"Angiogenesis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000455144","article-title":"Significance of Vasculogenic Mimicry Formation in Gastric Carcinoma","volume":"40","author":"Lv","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s12253-018-0496-3","article-title":"Correlation Between Tumor Vasculogenic Mimicry and Poor Prognosis of Human Digestive Cancer Patients: A Systematic Review and Meta-Analysis","volume":"25","author":"Ren","year":"2019","journal-title":"Pathol. Oncol. Res. POR"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-13-0949","article-title":"UPARANT: A Urokinase Receptor-Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and in vitro and in vivo Potency","volume":"13","author":"Carriero","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"12169","DOI":"10.1038\/s41598-019-47900-3","article-title":"Structure-Function Relationship of an Urokinase Receptor-Derived Peptide Which Inhibits the Formyl Peptide Receptor Type 1 Activity","volume":"9","author":"Minopoli","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cren, P.-Y., Lebellec, L., Ryckewaert, T., and Penel, N. (2020). Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.594445"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13894","DOI":"10.1038\/s41598-017-14341-9","article-title":"Aberrant Glioblastoma Neovascularization Patterns and Their Correlation with DCE-MRI-Derived Parameters Following Temozolomide and Bevacizumab Treatment","volume":"7","author":"Xue","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1756-9966-31-37","article-title":"Enhancement of Radiation Response with Bevacizumab","volume":"31","author":"Hoang","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3892\/etm.2022.11493","article-title":"An in Vitro Study on the Effect of Bevacizumab on Endothelial Cell Proliferation and VEGF Concentration Level in Patients with Hereditary Hemorrhagic Telangiectasia","volume":"24","author":"Sadick","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Alonso-Diez, \u00c1., C\u00e1ceres, S., Pe\u00f1a, L., Crespo, B., and Illera, J.C. (2021). Anti-Angiogenic Treatments Interact with Steroid Secretion in Inflammatory Breast Cancer Triple Negative Cell Lines. Cancers, 13.","DOI":"10.3390\/cancers13153668"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-020-01288-1","article-title":"Mechanisms of Vasculogenic Mimicry in Hypoxic Tumor Microenvironments","volume":"20","author":"Wei","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor Angiogenesis: Causes, Consequences, Challenges and Opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12272-025-01545-1","article-title":"Targeting Vascular Endothelial Growth Receptor-2 (VEGFR-2): Structural Biology, Functional Insights, and Therapeutic Resistance","volume":"48","author":"Shah","year":"2025","journal-title":"Arch. Pharm. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cytogfr.2014.07.009","article-title":"The Multifaceted Activity of VEGF in Angiogenesis\u2014Implications for Therapy Responses","volume":"25","author":"Moens","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Masucci, M.T., Minopoli, M., Di Carluccio, G., Motti, M.L., and Carriero, M.V. (2022). Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer. Cancers, 14.","DOI":"10.3390\/cancers14030498"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Bifulco, K., Longanesi-Cattani, I., Franco, P., Pavone, V., Mugione, P., Di Carluccio, G., Masucci, M.T., Arra, C., Pirozzi, G., and Stoppelli, M.P. (2012). Single Amino Acid Substitutions in the Chemotactic Sequence of Urokinase Receptor Modulate Cell Migration and Invasion. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044806"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1158\/1535-7163.MCT-13-0077","article-title":"A Urokinase Receptor\u2013Derived Peptide Inhibiting VEGF-Dependent Directional Migration and Vascular Sprouting","volume":"12","author":"Bifulco","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","article-title":"Antiangiogenic Therapy: Impact on Invasion, Disease Progression, and Metastasis","volume":"8","author":"Ebos","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Bruna-Mej\u00edas, A., Silva-Bravo, V., Moyano Valarezo, L., Delgado-Retamal, M.F., Nazar-Izquierdo, D., Aguilar-Aguirre, I., Nova-Baeza, P., Orellana-Donoso, M., Suazo-Santib\u00e1\u00f1ez, A., and Guti\u00e9rrez-Espinoza, H. (2025). The Adverse Effects and Use of Bevacizumab in Patients with Glioblastoma: A Systematic Review and Meta-Analysis. Pharmaceuticals, 18.","DOI":"10.3390\/ph18060795"},{"key":"ref_53","first-page":"e1318","article-title":"Vascular Co-option and Vasculogenic Mimicry Mediate Resistance to Antiangiogenic Strategies","volume":"5","author":"Pezzella","year":"2022","journal-title":"Cancer Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Xia, Y., Wang, L., and Wang, Y. (2024). Targeted Anti-Angiogenesis Therapy for Advanced Osteosarcoma. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1413213"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/5\/392\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:31:27Z","timestamp":1772083887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/5\/392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cells15050392"],"URL":"https:\/\/doi.org\/10.3390\/cells15050392","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}